Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 9:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
HIV Infections
Interventions
Ampligen
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1990
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Covid19
Interventions
AntiCov-220, AntiCov-220 (placebo)
Drug
Lead sponsor
Nguyen Thi Trieu, MD
Individual
Eligibility
16 Years to 82 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Conditions
Cytomegalovirus Infection, Adenovirus Infection
Interventions
CMV/AdV specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Houston, Texas
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Conditions
PTSD
Interventions
Glecaprevir / Pibrentasvir Pill
Drug
Lead sponsor
White River Junction Veterans Affairs Medical Center
Federal
Eligibility
19 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
White River Junction, Vermont
Completed Early Phase 1 Interventional Accepts healthy volunteers

Long COVID-19 [11C]CPPC Study

NCT06223971
Conditions
COVID Long-Haul
Interventions
[11C]CPPC Injection
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
Interventions
Bictegravir, emtricitabine, and tenofovir alafenamide
Drug
Lead sponsor
CAN Community Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Clearwater, Florida • Ft. Pierce, Florida • Jacksonville, Florida + 6 more
Conditions
Post COVID-19 Condition, Post-COVID-19 Syndrome
Interventions
6-Week Self-Management Group
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Conditions
HIV Infections
Interventions
Abacavir sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
9 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Completed No phase listed Observational Results available

Swallowing Impairment After COVID-19 Infection

NCT04537650
Conditions
Covid19
Interventions
Videofluoroscopic Swallowing Study (VFSS)
Diagnostic Test
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions
Famotidine, Celecoxib, Placebo
Drug
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more
Completed Phase 3 Interventional Results available

Frontline Clinician Psilocybin Study

NCT05163496
Conditions
Burnout, Caregiver, Burnout, Professional, COVID-19, Depression, Post Traumatic Stress Disorder, Moral Injury
Interventions
Psilocybin (Usona Institute), Active placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Long COVID, Post-Acute COVID-19 Syndrome
Interventions
Amantadine, Physical, Occupational, Speech Therapy, Provider Counseling, Medications for symptoms management
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Long Covid
Interventions
Attention Training, Music Group
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
HIV Infections, Substance Use, Sexual Assault
Interventions
Enhanced intervention, Usual Care
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
17 Years to 25 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Covid19
Interventions
Not listed
Lead sponsor
Tulane University
Other
Eligibility
6 Months to 120 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
2
States / cities
New Orleans, Louisiana
Conditions
Acquired Immunodeficiency Syndrome, Stress Disorders, Post-Traumatic
Interventions
Questionnaires
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
15 Years to 25 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Stanford, California
Conditions
Post-acute COVID-19 (PACS), or "long COVID" Syndrome
Interventions
Surveys
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Murray, Utah
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
darbepoetin alfa, epoetin alfa, fatigue assessment and management, quality-of-life assessment
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Rabies
Interventions
CL184, HRIG, Placebo matching CL184
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
19 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Terminated Phase 2 Interventional Results available

LYT-100 in Post-acute COVID-19 Respiratory Disease

NCT04652518
Conditions
Covid19, Post-acute COVID-19 Respiratory Disease
Interventions
LYT-100, Placebo
Drug · Other
Lead sponsor
PureTech
Industry
Eligibility
18 Years to 80 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Florence, Alabama • Los Angeles, California + 12 more
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
imetelstat sodium, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 18 more
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
8
States / cities
Palo Alto, California • San Francisco, California • Chicago, Illinois + 4 more
Conditions
Papillomavirus Infections
Interventions
VGX-3100
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Winston-Salem, North Carolina • Hopwood, Pennsylvania • Philadelphia, Pennsylvania